Today: 22 January 2026
Subscribe
Browse Category

Pharmaceuticals News 16 January 2026 - 18 January 2026

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

Pfizer stock slips into MLK Day break as FDA fast-track fears and key dates loom

New York, January 18, 2026, 06:30 EST — Market closed Pfizer Inc (PFE) shares slipped 0.93% to $25.65 on Friday. Reuters reported that some drugmakers harbor quiet concerns over a White House-backed fast FDA review program, fearing it could increase legal risks if a rushed process overlooks safety problems. Pfizer has reportedly considered joining the initiative, according to Reuters. (Investing)…
18 January 2026
·····
Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Novo Nordisk stock rallies: Wegovy pill scripts and UK higher-dose nod put NOVO-B back in play

Copenhagen, January 17, 2026, 21:05 CET — The market has closed. Shares of Novo Nordisk A/S Class B jumped 6.5%, finishing Friday at 388.9 Danish crowns. The late-week surge put the stock in a stronger position ahead of Monday’s market open. Trading volume hit roughly 13.9 million shares amid a session that shifted alongside the news cycle. (Investing) This move…
17 January 2026
····
Roche stock price in focus: Goldman flips to neutral as ROG heads into Jan. 29 results

Roche stock price in focus: Goldman flips to neutral as ROG heads into Jan. 29 results

Zurich, Jan 17, 2026, 17:40 CET — The market has closed. Roche Holding shares (ROG.S) closed Friday 0.93% higher at 348.90 Swiss francs on the Swiss Exchange, a gain of 3.20 francs from Thursday’s finish. Swiss markets remain closed Saturday. (MarketScreener) The shift is significant as broker upgrades begin to reflect a rally that’s driven Roche’s valuation to tighter margins.…
17 January 2026
····
Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

Eli Lilly stock price in focus as FDA slips obesity pill deadline — what to watch in LLY next week

New York, Jan 17, 2026, 10:03 ET — Market closed. Eli Lilly shares ended Friday up 0.5%, closing at $1,038.40. Investors enter the week anticipating a delayed U.S. regulatory verdict on the drugmaker’s experimental obesity medication. The key issue now is timing. A postponed verdict on Lilly’s oral weight-loss drug comes amid a rapidly evolving race, where pills aim to…
17 January 2026
····
Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

Pfizer stock slips into holiday week as CEO filing, vaccine-policy row and biotech IPO news land

New York, January 17, 2026, 07:32 EST — Market closed. Shares of Pfizer Inc (PFE) closed Friday down 0.9% at $25.65. Investors wrestled with a jumble of policy updates, regulatory filings, and a biotech IPO that dragged Pfizer’s name back into the paperwork spotlight. The next real hurdle for the stock arrives Tuesday. U.S. markets shut Monday for Martin Luther…
17 January 2026
···
Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Novo Nordisk stock jumps on Wegovy pill scripts and UK high-dose nod — what to watch next week

Copenhagen, Jan 17, 2026, 10:59 CET — Market closed. Novo Nordisk shares gained 6.5% on Friday, closing at 388.9 Danish crowns, positioning the stock for a notable open Monday. In New York, the company’s ADRs jumped 9.1% to finish at $62.33. (Investing) This move is crucial as investors seek confirmation that Novo’s new Wegovy pill will maintain its first-to-market advantage…
17 January 2026
····
GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

GSK stock slips into the weekend as insider dividend reinvestment filings land; eyes on Feb. 4 results

London, January 17, 2026, 07:58 GMT — The market has closed. Shares of GSK plc slipped 1.7% to 1,817 pence on Friday, lagging behind a flat FTSE 100 as volume spiked late in the session. The stock closed 11.7% below its 52-week peak of 2,058 pence reached on Dec. 19. Trading volume hit 12.6 million shares, well above the 50-day…
17 January 2026
····
Merck stock price slips as FDA fast-track doubts surface before MRK earnings

Merck stock price slips as FDA fast-track doubts surface before MRK earnings

NEW YORK, Jan 16, 2026, 21:08 EST — Market closed. Shares of Merck & Co (MRK.N) dipped 1.9% Friday, closing at $108.83 following a range of $108.49 to $111.19. The stock kicked off the session at $110.63 with roughly 14.9 million shares traded. The drop came as investors digested a Reuters report revealing some drugmakers’ unease over the FDA Commissioner’s…
17 January 2026
····
AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

AbbVie stock heads into long weekend lower after mixed Epkinly trial readout; earnings next

New York, Jan 16, 2026, 20:14 EST — Market closed AbbVie shares slipped 1.1% to close at $214.35 on Friday following mixed late-stage results for its lymphoma treatment, epcoritamab. In after-hours trading, the stock was last seen near $214.66, as U.S. indexes showed little movement. (Investing) The readout arrives at a tough time for bulls. AbbVie is hustling to keep…
17 January 2026
···
Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

Eli Lilly stock: FDA pushes orforglipron decision to April 10 as lawsuit adds another overhang

New York, January 16, 2026, 17:39 EST — After-hours Eli Lilly (LLY.N) shares ticked up about 0.5%, closing at $1,038.40 in after-hours trading Friday, after swinging between $1,019.00 and $1,049.83 during the session. Internal documents reviewed by Reuters revealed the U.S. FDA has pushed back its target decision date for Lilly’s obesity drug orforglipron to April 10. Holly Fernandez Lynch,…
17 January 2026
····
Merck stock slips as FDA fast-track questions build and earnings near

Merck stock slips as FDA fast-track questions build and earnings near

New York, January 16, 2026, 15:04 EST — Regular session Merck & Co shares (MRK.N) dropped roughly 1.2% to $109.65 on Friday, erasing earlier gains and settling near the session lows. The stock swung between $108.49 and $111.19 during the day, with around 7.6 million shares changing hands by the afternoon. The decline followed weakness in large-cap healthcare, despite the…
16 January 2026
···
AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

AbbVie stock slides on mixed lymphoma trial readout as investors eye the next catalyst

New York, Jan 16, 2026, 14:14 ET — Regular session AbbVie Inc shares dropped 1.1% to $214.35 Friday afternoon after releasing mixed results from a late-stage trial of its lymphoma drug epcoritamab. The Phase 3 study hit its primary endpoint, showing improved progression-free survival — meaning patients lived longer without their cancer worsening — but it missed a statistically significant…
16 January 2026
····
1 2 3 4 5 … 45

Stock Market Today

  • Pro Medicus Leverages US Market to Strengthen Competitive Edge in Health-Tech
    January 22, 2026, 5:15 AM EST. Pro Medicus (ASX:PME), known for its advanced radiology imaging software and AI capabilities, is strengthening its position in the US hospital market through long-term contracts. The company competes effectively against larger legacy vendors, supporting its premium valuation despite recent share price declines. Investor focus centers on Pro Medicus' ability to sustain contract wins, margins, and cash flow ahead of its February 12, 2026 earnings report. Market sentiment remains fragile amid high valuation risks and expectations. Divergent fair value estimates, ranging from A$68.65 to over A$500, highlight varying investor perspectives on its growth prospects and US footprint. Pro Medicus' premium positioning in the specialized health-tech arena underpins its broader investment narrative.
Go toTop